Management of Obstructive Jaundice

Diagnostic Approach

• Abdominal ultrasound is the first-line imaging study for evaluating jaundice, with high sensitivity (32-100%) and specificity (71-97%) for detecting biliary obstruction 1
• CT abdomen with IV contrast or MRI abdomen with MRCP are equivalent alternatives for further evaluation when ultrasound findings are inconclusive 1
• Brush cytology and/or endoscopic biopsy should be obtained before any attempt at endoscopic therapy to help exclude malignancy 2

Treatment Algorithm Based on Etiology

Biliary Drainage Options

• Endoscopic stent insertion (ERCP) is the preferred first-line approach due to lower morbidity and procedure-related mortality rates compared to percutaneous approaches 3
• Plastic stents are adequate for most patients with obstructive jaundice 4, 3
• Metal stents may be appropriate for patients with better than average life expectancy but who are unsuitable for surgical palliation 3
• Percutaneous approach is reserved for patients with proximal dominant strictures where endoscopic approach has failed 2
• Surgical bypass is preferred in patients with good performance status and small tumors who are likely to survive longer than six months 4, 3
• Surgical bypass offers better long-term patency than stenting 4

Antibiotic Management

• Perioperative antibiotics should be administered when injecting contrast agent into an obstructed duct to prevent cholangitis 2
• Patients with jaundice should have cultures of blood, urine, and ascites (if present) to rule out bacterial infections before intervention 1

Special Considerations

Timing of Biliary Decompression

• Urgent decompression is required for severe (grade 3) acute cholangitis 5
• Early decompression is needed for moderate (grade 2) acute cholangitis 5
• Mild (grade 1) acute cholangitis can be initially observed on medical treatment 5

Preoperative Biliary Drainage

• Preoperative biliary drainage may be necessary for patients undergoing neoadjuvant therapy before pancreatic resection 6
• Temporary stent placement with antibiotic coverage is recommended if symptoms of cholangitis or fever are present 6
• Preoperative biliary drainage may increase postoperative complications in patients going directly to surgery 6

Malignant Obstruction

• For patients with pancreatic cancer receiving chemotherapy, untreated obstructive jaundice may lead to biochemical derangements that preclude continuation of therapy unless biliary decompression is performed 7

Complications and Pitfalls

• Stent insertion complications include cholangitis, perforation, and stent occlusion due to bacterial biofilm and biliary sludge deposition 3
• Recurrent jaundice usually indicates stent occlusion rather than progressive disease 3

Evidence‑Based Management of Infection and Chemotherapy in Stage IV Colon Cancer with Malignant Biliary Obstruction

Infection Management

• Initiate broad‑spectrum intravenous antibiotics that cover Gram‑negative organisms (e.g., Escherichia coli) and anaerobes (e.g., Bacteroides fragilis) because these pathogens are most frequently implicated in infectious complications of colorectal cancer. 8
• Choose an empirical regimen that includes activity against extended‑spectrum β‑lactamase (ESBL)‑producing Enterobacteriaceae, reflecting the rising prevalence of these resistant organisms in community‑acquired infections. 8
• Plan a treatment course of 4–7 days, tailoring duration to clinical response criteria such as achievement of source control, resolution of fever, normalization of leukocyte count, and improvement of inflammatory markers. 8
• Adjust the antibiotic regimen promptly once microbiology results become available, narrowing spectrum according to identified pathogens and susceptibilities. 8

Chemotherapy Management

• After successful biliary drainage and if the patient’s performance status is adequate, resume the standard CAPOX regimen (capecitabine + oxaliplatin) for stage IV colon cancer, as recommended by the NCCN guidelines. [9][10]

• Do not add routine prophylactic antibiotics (e.g., doxycycline) to the chemotherapy protocol unless epidermal growth factor receptor (EGFR) inhibitors such as cetuximab or panitumumab are incorporated, per NCCN recommendations. [9][10]